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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
adjuvant therapy with Omega-3 fatty acids (fish oil) improves joint tenderness in patients with
Rheumatoid Arthritis.
STUDY DESIGN: Review of 3 double-blind, randomized controlled trials from 2010- 2017.
DATA SOURCES: Three peer-reviewed journal articles written in English were found using
PubMed. Articles were selected based on their relevance to the question and whether the
outcome measured was patient-oriented evidence that matters.
OUTCOME(S) MEASURED: All articles analyzed the effectiveness of adjunctive treatment
with omega-3 fatty acids on the improvement of joint tenderness in patients with rheumatoid
arthritis. The overall outcome measured was the number of tender joints before and after
treatment with omega-3 fatty acids in addition to traditional DMARD therapy.
RESULTS: All three studies found statistically significant improvement in joint tenderness with
adjunctive treatment with omega-3 fatty acid supplementation. Different concentrations of fish
oil containing EPA and DHA were administered to the treatment groups and compared to either
a control or placebo group. Patients complied with the same traditional DMARD therapy in each
individual study, though the therapies differed between studies.
CONCLUSIONS: This review provides evidence from three separate studies that fish oil
supplementation decreases the number of tender joints in patients with active RA. Future
research should focus on increasing sample size and generalizability of research findings, and
determine the effectiveness of fish oil combined with different DMARD therapies.
KEY WORDS: Fish oils, Fatty acids, Omega-3, and Rheumatoid Arthritis.
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, progressive, symmetric, inflammatory arthritis
affecting 1.3 million U.S adults, about 0.6% of the population.1 Middle-aged women are affected
two times more than men and pose the highest risk. 2 According to a study done in 2009,
estimated the overall cost of care for RA patients was $39.2 billion.3 In addition, a study in 2008
found that RA accounted for 36.5 million health care visits.4 Although RA does have genetic
associations, the cause is still not well understood despite years of research.
RA is an autoimmune condition causing an immune-mediated attack on joints leading to
significant inflammation, pain, and decreased joint mobility and function. Most of the
inflammation is caused by the proliferation of the joint synovium, where there is an
accumulation of inflammatory immune cells such as neutrophils, CD4 helper T cells, B cells, and
macrophages. Accumulation of inflammatory cells causes pain and swelling, further leading to
the production and infiltration of inflammatory mediators such as tumor necrosis factor,
interleukins, and prostaglandins.5 Multiple joints are affected in a symmetric distribution
throughout the body, where inflammation and immune-mediated reactions cause erosion of
cartilage and bone in the joint space.5
Disease-modifying anti-rheumatic drug (DMARD) therapy remains the mainstay of
treatment for rheumatoid arthritis, aimed at managing symptoms and decreasing joint
destruction.6 There are conventional, targeted, and biologic DMARD options which all are
prescribed with the intent to minimize the inflammatory effects of this condition by targeting
specific inflammatory molecules; drug examples include, methotrexate, hydroxychloroquine,
sulfasalazine, leflunomide, corticosteroids, Janus kinase inhibitors, tumor necrosis factor
antagonists, interleukin-1 receptor antagonists, and interleukin-6 receptor antagonists.7 In severe

Fauteux, Fish oil in Rheumatoid Arthritis 2
cases, surgical joint replacement may be needed late in the disease.7 Rheumatoid arthritis
currently has no ‘cure’ through medical therapy. All of the medications listed above are only
capable of decreasing disease severity and preventing further damage to joint margins. Each
DMARD option comes with significant side effects that vary amongst individuals, such as hair
loss, allergic reactions, gastrointestinal discomfort, mouth sores, hepatotoxicity, and more.7
Harsh side effects and high risk of individualized adverse drug reactions from DMARD therapy
have led to multiple clinical trials exploring alternate drug therapies, such as omega-3 fatty acids.
Omega-3 fatty acids target different inflammatory molecules than traditional DMARD therapy,
altering the innate inflammatory pathway at a different angle with less adverse side effects.8
Arachidonic acid (AA) is an omega-6 fatty acid that sits in the phospholipid bilayer of
cell membranes.8 AA can act as a precursor for many different enzymes involved in the
inflammatory process such as prostaglandins and leukotrienes. Increased amounts of omega-3
fatty acids found in fish oil, including eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), have an inhibitory effect on AA; thus leading to a decreased production of inflammatory
molecules.8 This mechanism of omega-3 fatty acid proliferation is the focus for determining the
anti-inflammatory effects that adjunctive supplementation with fish oil has on individuals with
RA.8
OBJECTIVE
The objective of this selective EBM review is to determine whether adjuvant therapy
with omega-3 fatty acids (fish oil) improves joint tenderness in patients with rheumatoid arthritis.
METHODS:
All three studies were peer-reviewed journal articles written in English, dated from 20102017. Articles were selected using PubMed as a research database. Keywords used in the search
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included, “Fish Oils," "Fatty acids," "Omega-3," and "Rheumatoid Arthritis." Inclusion criteria
were as follows: Omega-3 fatty acid supplementation for previously diagnosed Rheumatoid
Arthritis in an adult, randomized control trials within the past ten years, and measurement of the
patient-oriented outcome of joint tenderness. Exclusion criteria were also the same for all three
articles including children less than 18 years old, outcomes that were not patient-oriented, and an
article that was not a double-blind, randomized control trial. Detailed descriptions of both
inclusion and exclusion criteria for each individual study is provided in Table 1. The diagnosis of
RA was based on criteria from the American Rheumatism Association, Association of
Rheumatology America, and the American College of Rheumatology from the 2010 revision.
Fish oil supplements, including varying concentrations of EPA and DHA, were used as the
clinical intervention with a control group or a placebo group as a comparison. The summary of
statistics used was both mean change from baseline and p-values.
OUTCOMES MEASURED:
This review focused on determining the mean change from baseline of the number of
tender joints both before and after the intervention. Data collection in all articles was based on
the subjective assessment by the patient of their total number of tender joints before and after the
completion of the supplemental treatment. The Disease Assessment Score (DAS-28) takes into
account tender joint count, erythrocyte sedimentation rate, and C-reactive protein levels. The
visual analog scale (VAS) is a continuous scale that ranges from zero, signifying no pain, to 100,
signifying excruciating pain.5 Veselinovic et al. made assessments at baseline and at three
months using the DAS-28 and VAS.5 Rajaei et al. made assessments at baseline and every four
weeks for three months using both DAS-28 and VAS.6 Bahadori et al. made assessments at
baseline and week one, two, four, 11, and 22 using a trained physician to manually palpate the
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Table 1. - Demographics and Characteristics of Studies
Study

Type

Age
(yrs)
54-62

Inclusion
Criteria
RA diagnosed
according to the
ACRA criteria.

Exclusion
Criteria
Stable doses of
MTX of at least 10
mg/week and of
corticosteroids up
to 10 mg/ day of
prednisolone were
required 1 month
before enrollment.

W/D

Interventions

RCT

# of
Pts
24

Bahad
ori B,
et al.
20109

11

Rajaei
E, et
al.
20156

RCT

60

20-70

Clinical evaluation
and diagnosis of
RA.
Exclusion criteria:
Diagnosis > 6
months, bone
deformities,
metabolic and
gastrointestinal
diseases,
medication dose
fluctuation, use of
Omega-3 fatty
acids supplements,
digestive problems
& severe infection.

11

Veseli
novic
M, et
al.
20175

RCT

60

Mean
age
63.1
± 9.6

RA diagnosis
based on the ACR
2010 criteria. On
dosage of NSAIDs
and/or steroids
consistently for at
least 1 month, and
unchanged during
the study, while
the dose of
DMARDs had to
be stable for at
least 2 months.

Exclusion
Continued:
AST, ALT, or
Creatinine levels
higher than 1.5
times the
maximum normal
limit, total
bilirubin levels
more than 1.8
mg/dL,
incompletely
finishing the 12week treatment
course, or absence
from periodical
examination
sessions.
Chronic renal,
liver or heart ds,
DM, smoking,
uncontrolled HTN,
hyperlipidemia, a
family history of
cardiovascular ds,
premature
menopause, a
severe folic acid,
vitamin B6 or B12
deficiency, and
other arthritis.

0.20 g of fish
oil per kg with
a specific
combination
of EPA, DHA,
α-linolenic
acid,
docosapentaen
oic acid, or a
placebo. All
IV for 4 hours
over 14 days.
Patients in the
omega-3
group
consumed 2
omega - 3
capsules daily
which
contained 1.8
and 2.1 grams
of EPA and
DHA.

0

5 g of fish oil
with 1 g of
concentrated
fish oil with
300 mg of
DHA, 200 mg
of EPA, and
100 mg of
other n-3
PUFAs daily
after meals.
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patient’s joints and mark the number of tender joints on a ‘joint mannequin.’9 This review only
focused on analyzing the mean change from baseline of joint tenderness as a patient-oriented
evidence that matters (POEM), rather than using values from the DAS-28 and VAS.
RESULTS:
Veselinovic et al. carried out a double-blind, randomized controlled trial on 60 female
patients with a mean age of 63.1 ± 9.6 years.5 Each patient had an established diagnosis of RA as
determined by the American College of Rheumatology 2010 revised criteria, who were currently
on the exact same antirheumatic therapy.5 This therapy included up to 10 milligrams per day of
prednisolone, 15 milligrams per week of oral methotrexate, 10 milligrams per week of folic acid,
and non-steroidal anti-inflammatory drugs (NSAIDs) as needed.5 Alternate RA drug therapy was
a component of the exclusion criteria; additional inclusion and exclusion criteria can be found in
Table 1. Patient demographics were similar in age, body mass index (BMI), and disease duration.
No patients dropped out of the study. Measurements of the tender joint count were taken at
baseline with a follow-up assessment at 12 weeks.
The researchers randomly placed patients in three groups of 20 members.5 The first group
took 5 grams of fish oil daily after meals.5 The capsules were Omega-3 Cardio® gel capsules,
each with 1 gram of concentrated fish oil with 300 milligrams of DHA, 200 milligrams of EPA,
and 100 milligrams of other n-3 polyunsaturated fatty acids (PUFAs).5 The control group
received the same regimen of antirheumatic drug therapy as the treatment group, without
administration of Omega-3 Cardio® gel capsules. The third group received a treatment that is not
applicable to this this review. In order to assess the effect of omega-3 fatty acids as adjunctive
therapy, joint tenderness was assessed as a subjective measurement by each patient, and the
researchers determined the mean change from baseline as demonstrated in Table 2. The mean
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change from baseline in the group that received treatment with omega-3 fatty acids saw
substantial improvement in joint tenderness. Mean joint tenderness changed from 6.2 to 3.3 in
the treatment group and only 5.0 to 4.6 in the control group. The p-value was calculated to be
<0.001, solidifying the statistical significance of these findings. Adverse reactions were only
found in two patients who experienced gastrointestinal discomfort with mild diarrhea, abdominal
pain, and dyspepsia. No other side effects were reported.5
Table 2. – Mean Change From Baseline of Joint Tenderness, Veselinovic et al.5
Number of tender joints
Omega-3
Control
Baseline
6.2 ± 2.0
5.0 ± 2.0
End of study
3.3 ± 1.5
4.6 ± 1.6
Mean change from baseline
-2.4[LARGE]
-0.4[SMALL]
P-value
<0.001
Rajaei et al. carried out a double-blind randomized controlled trial on 60 patients, 49
females and 11 males diagnosed with RA according to the Association of Rheumatology
America criteria.6 The mean age was 42.4 ± 7 years and 49 patients successfully completed the
study with only 11 dropouts. Detailed inclusion and exclusion criteria are included in Table 1.
All subjects were similar in age, sex, drug consumption, and disease duration.6
The same maintenance antirheumatic therapy was given to each patient that consisted of
5 milligrams of prednisone twice a day, 200 milligrams of hydroxychloroquine once a day, 0.2
milligrams per kilogram of body weight of methotrexate per week, and 25 milligrams of
indomethacin three times a day. Patients were randomly placed in two separate groups, one
receiving two omega-3 capsules every day containing 1.8 grams of EPA and 2.1 grams of DHA.
The other group received a placebo pill that contained starch and closely resembled an omega-3
product created by Anzan Pharmaceutical Company. All patients reported compliance with the
medications given. Assessments of subjective joint tenderness were made at baseline and every
four weeks for three months throughout the treatment. The effectiveness of omega-3 treatment
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was determined by 50% improvement seen in 89% of the treatment group (experimental event
rate, EER= 0.89) and only 13% of the placebo group (control event rate, CER= 0.13) as shown in
Table 3. Table 3 shows the number needed to treat (NNT) value of 2, meaning for every two
patients with rheumatoid arthritis, at least 1 patient will have a 50% improvement in joint
tenderness while taking omega-3 fatty acids, showing a statistically significant improvement (Pvalue = <0.05). The Absolute Benefit Increase (ABI) of this treatment was calculated at 0.76 as
shown in Table 3, demonstrating the increase in improvement of joint tenderness due to the
intervention. Table 4 demonstrates the mean change from baseline of joint tenderness in both the
placebo and treatment groups. This is calculated to be a decrease in a tender joint count of 19 in
the treatment group and only four in the placebo group. Minor adverse reactions from the
treatment caused two patients to drop out who complained of vomiting and flatulence.6
Table 3. –ABI, NNT, and statistical significance; Rajaei et al.6
CER
EER
Absolute benefit increase
Number needed to treat
(ABI)
(NNT)
0.13
0.89
0.89-0.13 = 0.76
1/0.76 = 1.3= 2

P-value
<0.05

Table 4. – Mean change from baseline of joint tenderness, Rajaei et al.6
Number of tender joints
Omega-3
Placebo
Baseline
21
24
End of study
5
20
Mean change from baseline
-19
-4
P-value
<0.05
Bahadori et al. carried out a double-blind, randomized controlled trial including 24
patients, 23 females and one male, with active RA as diagnosed by the American Rheumatism
Association criteria.9 The mean age was 58 ± 4 years in the treatment group and 59 ± 2 in the
placebo group. The initial demographic comparison of the patients was found to be similar in age
and weight. In order to be included in the study, each patient was required to complete one
month of 10 milligrams per week of methotrexate and 10 milligrams per day of prednisolone.
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NSAIDs and paracetamol were allowed as needed and all patients were encouraged to stay on a
low AA diet throughout the study. Detailed inclusion and exclusion criteria can be found in
Table 1. Only 13 of the 24 patients successfully completed the study.9
Researchers randomly placed patients into a treatment group or placebo group and both
received inpatient intravenous treatments with follow up at one, two, four, 11, and 22 weeks post
therapy. The treatment group received 0.20 grams of fish oil emulsion per kilogram of body
weight. Researchers chose Omegaven®, which was a 100 mL containing 6.56 gram of omega-3
PUFA, comprising 2.82 gram of EPA, 3.09 gram of DHA, 0.20 gram α -linolenic acid, and 0.45
gram of docosapentaenoic acid. The control group received an equal amount of 0.9% normal
saline intravenously, which was similar in color to the fish oil emulsion. Both groups were
treated for four hours every day for 14 consecutive days. A trained physician who determined the
number of tender joints through manual palpation performed each assessment and documented
the findings on a joint mannequin.9
To determine the effectiveness of omega-3 fatty acid treatment compared to the placebo,
a mean change from baseline value was calculated as shown in Table 5. The baseline value of
tender joints was 18 in the treatment group and 17 in the placebo group. Assessments at week 22
demonstrated that the treatment group had a mean of 15.5 fewer swollen joints and the placebo
had only nine fewer swollen joints, demonstrating a statistically significant improvement (Pvalue = 0.033). Patients in both the omega-3 group and the placebo group experienced adverse
Table 5. - Mean change from baseline of the tender joint count, Bahadori et al.9
Number of tender joints
Baseline
End of study-week 22
Mean change from baseline
P-value

Omega-3
18
2.5
-15.5

Placebo
17
8
-9
0.033
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reactions in a very similar distribution, making it less likely that the adverse reactions were
caused by the fish oil treatment. Symptoms reported included local infusion reaction, feeling
uncomfortable, nausea, diarrhea, headache, and depression.9
DISCUSSION:
Rheumatoid arthritis is a common inflammatory arthritis that causes significant pain and
discomfort with decreased joint mobility. This review highlights the effectiveness of adjunctive
omega-3 fatty acid supplementation on the decrease in the number of tender joints in patients
with active RA receiving traditional DMARD therapy. Both Rajaei et al6 and Veselinovic et al5
used oral capsules of omega-3 fatty acids with varying amounts of EPA and DHA, while
Bahadori et al9 used intravenous treatment. The effectiveness of omega-3 fatty acids was shown
to significantly improve the number of tender joints in each patient population. Baseline
DMARD therapy was relatively consistent across studies including methotrexate or
hydroxychloroquine, folic acid, and a corticosteroid agent. Although these treatments are not
identical, the important point to focus on is the time in which the subjective joint tenderness was
recorded. Baseline measurements were made while patients were already taking DMARD
therapy. The end measurement was taken only after omega-3 fatty acids were added to their
treatment regimen. Although each study delivered treatment in different ways and had varying
baseline DMARD therapy, all three study results implied the significant positive impact that
adjunctive treatment with omega-3 fatty acids has specifically on joint tenderness.
A limitation of this review was the low number of articles selected for analysis on this
topic; future reviews would benefit from more than five randomized controlled trials. The
limitations found in all three studies included a low sample size and predominantly female
populations. The route of administration and varying amounts of EPA, DHA, and other
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ingredients in the omega-3 supplement were also inconsistent across all three studies. The
subjectivity of joint tenderness as the POEM leads to increased variability in all three studies.
Veselinovic et al discussed the lack of a blinded placebo control group as a limitation, which was
chosen due to the ingredients in most placebo pills having a possible impact on study outcome.5
Bahadori et al had a large number of dropouts combined with the smallest sample size out of all
three studies, making it difficult to relate the research findings to the general population. Lastly,
a large limitation that is difficult to control in this research is the varying impact that traditional
DMARD therapy has on each individual patient. Rather than fish oil supplementation causing
improved joint tenderness alone, it’s likely a combination of both DMARD therapy and fish oil
improves the symptoms of joint tenderness.
Omega-3 fatty acids are sold as fish oil tablets and contain varying concentrations of EPA
and DHA. This affordable product is readily available in most drug stores in the United States
and is sold as an over-the-counter medication not covered by insurance. Few omega-3 fatty acid
supplements are sold as prescription products; however, Lovaza® is a combination of EPA and
DHA ethyl esters, is one example that may be covered by insurance.10

CONCLUSION:
All three studies provided statistically significant evidence suggesting the positive impact
that omega-3 fatty acid supplementation has on joint tenderness on patients with active
rheumatoid arthritis. The number of tender joints decreased substantially in each treatment group
that received fish oil as adjunctive therapy to traditional DMARD therapy when compared to the
control groups. Future research should aim at broadening the sample populations including more
research on males with RA and increasing the sample size. Ideally, one large study with several
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hundred adult RA patients of both genders diagnosed based on the same criteria, treated with the
same baseline DMARD therapy, and receiving the same concentrations of EPA and DHA in the
fish oil supplementation would provide more valid results. Controlling for extraneous factors that
impact the results of this intervention will be difficult but could provide beneficial evidence to
improve both joint function and tenderness in patients with RA.
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